Insulet Corporation (PODD) Stock

Understand Insulet Corporation: how it makes money

Insulet makes and sells insulin delivery systems for people with insulin-dependent diabetes, mainly the Omnipod System disposable tubeless insulin pod (worn up to three days) and its wireless handheld personal diabetes manager, and earns revenue from selling these products through independent distributors, pharmacy channels, and direct sales across the U.S., Canada, Europe, the Middle East, and Australia.

The profit model is driven by recurring demand for the disposable Omnipod tubeless insulin pod (designed for up to three days of wear) and continued device ecosystem use, monetized through channel sales, with the U.S. and international mix affecting how much of that pod-driven consumption shows up in each region’s revenue.

Business quality (Solid): Clear operating signals are available from Omnipod 5 adoption and the U.S. versus international revenue split, but the provided data does not include customer counts, retention, or other common operating metrics, so trend interpretation depends heavily on the adoption percentages and regional revenue.

Valuation: At 37× earnings, PODD trades 14% above the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

• High U.S. Omnipod 5 usage indicates strong product penetration in the company’s largest market (90% of U.S. customers using Omnipod 5): When most customers use the newest system, it can support steadier demand for the associated disposable pod ecosystem.
• International revenue remains meaningful (0.21B) alongside U.S. revenue (0.57B), showing the business is not purely U.S.-only: A continuing international base can diversify where consumption-related revenue comes from.

Bear case

• International Omnipod 5 penetration is much lower than the U.S. (30% internationally versus 90% in the U.S.): Slower international adoption can limit future growth in the regions that are currently less penetrated.
• There is a cost of revenue charge related to voluntary medical device correction (0.03B): Device correction-related costs can pressure margins and highlight operational and quality risks.

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

• Solventum Corporation (SOLV)
• Baxter International Inc. (BAX)
• Penumbra, Inc. (PEN)
• Globus Medical, Inc. (GMED)
• Glaukos Corporation (GKOS)
• Teleflex Incorporated (TFX)
• MiniMed Group, Inc. (MMED)
• Merit Medical Systems, Inc. (MMSI)